Li, J. S., E. L. Eisenstein, H. G. Grabowski, E. D. Reid, B. Mangum, K. A. Schulman, J. V. Goldsmith, M. D. Murphy, R. M. Califf, and D. K. Benjamin Jr. 2007. Economic return of clinical trials performed under the pediatric exclusivity program. Journal of the American Medical Association 297(5):480–488.

Lloyd, I. 2002–2003. New technologies, products in development, and attrition rates: R&D revolution still around the corner. PAREXEL’s pharmaceutical R&D statistical sourcebook. Waltham, MA: PAREXEL International Corporation.

Owens, J. 2007. 2006 drug approvals: Finding the niche. Nature Reviews Drug Discovery 6:99–100.

Platt, R. 2007. Using health plan data to improve post-marketing safety. http://www.iom.edu/Object.File/Master/41/443/Platt%20slides.pdf (accessed July 17, 2007).

Walker, A. 2007. Routine healthcare surveillance is here. http://www.iom.edu/Object.File/Master/41/375/Walker%20slides.pdf (accessed July 17, 2007).

Wilensky, G. R. 2006. Developing a center for comparative effectiveness information. Health Affairs 25(6):w572–w585.

Young, R. C., C. R. Aldige, D. Balma, J. G. Bartlett, E. J. Benz, W. P. Bro, M. A. Caligiuri, B. A. Chabner, W. S. Dalton, N. Davenport-Ennis, M. A. Friedman, W. N. Hait, G. D. Hammond, P. J. Limburg, S. Lippman, H. K. Lyerly, J. L. Marshall, K. H. Mooney, J. M. Olefsky, R. L. Schilsky, E. V. Sigal, and J. W. Yates. 2007. Drug safety and drug efficacy: Two sides of the same coin (A White Paper Report). http://www.focr.org/drugsafetyreport/drugsafetyreport.pdf (accessed May 9, 2007).

Zarin, D. 2007. Resource implications of IOM recommendations for trial registration and results database. http://www.iom.edu/Object.File/Master/41/379/Zarin%20slides.pdf (accessed July 17, 2007).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement